Global Cephalosporin Drugs Market 2015-2019 is a new research report added by Sandlerresearch.org under the Pharmaceutical category. Cephalosporins are bactericidal antibiotics and act by inhibiting cell wall synthesis. They inhibit a wide variety of gram-positive and gram-negative bacteria. They are considered broad-spectrum antibiotics with similar activities to those of ampicillin. They are sometimes grouped into “generations” by their antimicrobial properties. Cephalosporin drugs can be grouped into five classes or generations. The gram-negative antimicrobial property significantly increases with each newer generation of cephalosporin.

The analysts forecast global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, This report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.

The report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. This report includes a discussion of the key vendors operating in this market.

Key regions

Key vendors

• Allergan
• Astellas
• Bristol-Myers Squibb
• GlaxoSmithKline
• Merck
• Pfizer
• Sandoz
• Teva Pharmaceuticals

Inquire for more information @ http://www.sandlerresearch.org/inquire-before-buying?rname=44037

Single User License USD 3000

Other prominent vendors

• Abbott
• Aspen Pharmacare
• AstraZeneca
• Aurobindo Pharma
• Basilea Pharmaceuticals
• Baxter
• Biocon
• Corden Pharma
• Cornerstone Therapeutics
• Eli Lilly
• F. Hoffmann-La Roche
• Flynn Pharma
• Hospira
• Incepta Pharmaceuticals
• Johnson & Johnson
• Kyorin Pharmaceutical
• Lupin Pharmaceuticals
• Orchid Pharma
• Par Pharmaceutical
• Pernix Therapeutics
• Sanofi
• Shionogi
• Sun Pharmaceutical
• Takeda Pharma
• Theravance Biopharma
• Wockhardt

Market driver

• Special regulatory designation for pipeline molecules

Market challenge

• Development of drug resistance

Market trend

• Use of combination therapies

Key questions answered in this report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?